Synergistic Effect of Mutations in the Amyloidogenic Core of Human Amylin (hAM) Affords a New Potent Inhibitor of hAM Fibrillation: Computational Design and Experimental Validation.

Abstract excerpt

The human amylin, hAM, also known as the human islet amyloid polypeptide (hIAPP), fibrils are identified as a substantial risk element in type 2 diabetes (T2D). Thus, targeting hAM fibrillation could significantly influence the prevention and treatment of T2D. In this work, a library of computationally designed peptides based on the hAM amyloidogenic sequence NFGAILSS, an effective inhibitor of hAM fibrillation,...

Topics

Join the communities discussing this publication.

• Amyloid
• Diabetes Mellitus, Type 2
• Drug Design
• Islet Amyloid Polypeptide
• Mutation